The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-25 and is reviewed periodically as new material appears.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual inspection of dry material |
| Solubility | Soluble in water | Polar aqueous solvent class |
| Typical storage | Minus 20 degrees Celsius, desiccated, dark | Applies to the lyophilized form |
| Purity assessment | Reversed-phase HPLC | Ultraviolet detection, area percent |
| Identity confirmation | Mass spectrometry | Measured mass compared with theoretical value |
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
In the United Kingdom, the National Union of Rail, Maritime and Transport Workers (RMT) put forward a slate of candidates in the 2009 European Parliament election under the banner of No to EU – Yes to Democracy, a broad left-wing Eurosceptic, alter-globalisation coalition involving socialist groups such as the Socialist Party, aiming to offer a leftist alternative among Eurosceptics to the anti-immigration and pro-business policies of the UK Independence Party. In the subsequent 2010 general election, the Trade Unionist and Socialist Coalition, launched in January 2010 and backed by Bob Crow, the leader of the RMT, along with other union leaders and the Socialist Party among other socialist groups, stood against the Labour Party in forty constituencies. The Trade Unionist and Socialist Coalition contested the 2011 local elections, having gained the endorsement of the RMT June 2010 conference, but it won no seats. Left Unity was also founded in 2013 after the film director Ken Loach appealed for a new party of the left to replace the Labour Party which he claimed had failed to oppose austerity and had shifted towards neoliberalism. Following a second consecutive defeat in the 2015 general election, self-described democratic socialist Jeremy Corbyn succeeded Ed Miliband as the Leader of the Labour Party, leading some to comment that New Labour was "dead and buried." In the 2017 general election, Labour increased its share of the vote to 40% but in the 2019 general election, Labour's vote share fell again.
Important properties of such local options are that they provide an optimal wound healing environment, while providing a constant local low dose release of ibuprofen while worn. If local treatment does not provide adequate pain reduction, it may be necessary for patients with chronic painful wounds to be prescribed additional systemic treatment for the physical component of their pain. Clinicians should consult with their prescribing colleagues referring to the WHO pain relief ladder of systemic treatment options for guidance. For every pharmacological intervention there are possible benefits and adverse events that the prescribing clinician will need to consider in conjunction with the wound care treatment team.
== Pharmacology == Vinblastine is a vinca alkaloid and a chemical analogue of vincristine. It binds tubulin, thereby inhibiting the assembly of microtubules. Vinblastine treatment causes M phase specific cell cycle arrest by disrupting microtubule assembly and proper formation of the mitotic spindle and the kinetochore, each of which are necessary for the separation of chromosomes during anaphase of mitosis. Toxicities include bone marrow suppression (which is dose-limiting), gastrointestinal toxicity, potent vesicant (blister-forming) activity, and extravasation injury (forms deep ulcers). Vinblastine paracrystals may be composed of tightly packed unpolymerized tubulin or microtubules. Vinblastine is reported to be an effective component of certain chemotherapy regimens, particularly when used with bleomycin and methotrexate in VBM chemotherapy for Stage IA or IIA Hodgkin lymphomas. The inclusion of vinblastine allows for lower doses of bleomycin and reduced overall toxicity with larger resting periods between chemotherapy cycles.
Sources: en.wikipedia.org
== Clinical implications == Immunisation of mothers against male-specific minor histocompatibility (H-Y) antigens has a pathogenic role in many cases of secondary recurrent miscarriage, that is, recurrent miscarriage in pregnancies succeeding a previous live birth. An example of this effect is that the male:female ratio of children born prior and subsequent to secondary recurrent miscarriage is 1.49 and 0.76 respectively.
==== Urinary system ==== The urinary system is the part of the excretory system that removes waste in the form of urine, comprising the kidneys, ureters, bladder, and the urethra. Other purposes of the urinary system include the regulation of blood volume and blood pressure; the control of electrolyte and metabolite levels; and the regulation of blood pH. Each kidney consists of functional units called nephrons. Following filtration of blood and further processing, the ureters carry urine from the kidneys into the urinary bladder. During urination, the urethra carries urine out of the bladder through the penis or vulva. The female and male urinary system are very similar, differing only in the length of the urethra.
John Macleod was a distinguished physiologist even before the discovery of insulin. He was elected a member of the Royal Society of Canada in 1919 and president of American Physiological Society in 1921. In 1923, Macleod was awarded the Cameron Prize for Therapeutics of the University of Edinburgh. Among the recognitions he received after 1923 were memberships of the Royal Society and the Royal Society of Edinburgh, corresponding membership of the German Academy of Sciences Leopoldina and honorary membership of the Regia Accademia Medica. After Banting's death in a plane crash in 1941, Best, with the help of his friends, continued to spread Banting's account of the discovery and tried to "write out" Macleod and Collip from the history books. Only in 1950 was the first independent revision of all sides of the story made, and it gave credit to all four members of the team. However, Macleod's public image remained tainted for decades after that. The 1976 ITV television drama Comets Among the Stars, with Ralph Richardson in the Macleod role, portrayed him as dark and repulsive. The second dramatization of the discovery, Glory Enough for All (1988), at last portrayed him more objectively. By then it was commonly accepted that Banting's and Best's story was distorted, since more documentation had been made publicly available, and it made a precise reconstruction of the events possible. Until Best died, this documentation had been kept secret for over 50 years by the University of Toronto, whose administration wanted to avoid fueling the controversy.
=== Precambrian bodies === The Earth formed around 4.6 billion years ago, with unicellular life emerging somewhat later after the cessation of the Late Heavy Bombardment, a period of intense asteroid impacts possibly caused by migration of the gas giant planets to their current orbits, however multicellularity and bodies are a relatively recent event in Earth's history. Bodies first started appearing towards the end of the Precambrian Era, during the Ediacaran period. The fossils of the Ediacaran period were first found in Southern Australia in the Ediacara Hills, hence the name. However these fossils were initially thought to be part of the Cambrian and it wasn't until the late 1950s when Martin Glaessner identified the fossils as actually being from the Precambrian era. The fossils that were found date to about 600 million years ago and are found in a variety of morphologies.
Sources: en.wikipedia.org
Dry powder is commonly held at minus twenty degrees Celsius, desiccated and away from light. Cold storage slows degradation of the lyophilized material.
Mass spectrometry establishes the molecular mass, and reversed-phase chromatography reports purity. A certificate of analysis typically combines both results.
Solutions degrade faster than the dry powder, particularly at room temperature. Portioning into single-use aliquots and freezing reduces losses from repeated thawing.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.